Nervio-X
DeviceAn 8-channel TIS device developed by NEURODOME Corporation.
NCT Number: NCT06477276
The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes. The intervention's safety and efficacy will be evaluated using an assessment incorporating depressive symptomatology, cognitive abilities, and daily functions.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Ruijin Hospital, Shanghai, Shanghai Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
An 8-channel TIS device developed by NEURODOME Corporation.
Time frame: 4 weeks
Time frame: Baseline, 1 week, 4 weeks and 8 weeks
Time frame: Baseline, 1 week and 8 weeks
Time frame: Baseline, 1 week, 4 weeks and 8 weeks
The SHAPS is a questionnaire that used to measure the severity of anhedonia, a common symptom in various mental health conditions.
Time frame: Baseline, 4 weeks and 8 weeks
Time frame: Baseline, 4 weeks and 8 weeks
Time frame: Baseline and 8 weeks
Time frame: Baseline and 8 weeks
Ruijin Hospital
Other
A Multicenter, Randomized, Controlled, Double-Blind Trial on the Efficacy and Safety of Amygdala Temporal Interference Stimulation for the Treatment of Depression.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details